Workflow
Burning Rock Reports Second Quarter 2025 Financial Results
Burning Rock DxBurning Rock Dx(US:BNR) GlobeNewswireยท2025-09-08 05:39

Core Viewpoint - Burning Rock Biotech Limited reported a 9.6% increase in total revenues for Q2 2025 compared to the same period in 2024, driven by growth in in-hospital and pharma research and development services, while central laboratory revenues declined. Financial Performance - Total revenues for Q2 2025 were RMB 148.5 million (US$ 20.7 million), up from RMB 135.5 million in Q2 2024 [2] - Cost of revenues increased slightly to RMB 40.5 million (US$ 5.6 million), a 0.9% rise from RMB 40.1 million in Q2 2024 [3] - Gross profit reached RMB 108.1 million (US$ 15.1 million), marking a 13.3% increase from RMB 95.4 million in Q2 2024, with a gross margin of 72.8% compared to 70.4% in the prior year [4] - Non-GAAP gross profit was RMB 110.5 million (US$ 15.4 million), an 8.4% increase from RMB 101.9 million in Q2 2024, with a non-GAAP gross margin of 74.4% [5] Operating Expenses - Operating expenses significantly decreased by 42.1% to RMB 119.6 million (US$ 16.7 million) from RMB 206.7 million in Q2 2024, attributed to budget control and headcount reduction [6] - Research and development expenses fell by 23.4% to RMB 49.8 million (US$ 6.9 million) from RMB 65.0 million in Q2 2024 [8] - Selling and marketing expenses decreased by 21.5% to RMB 38.4 million (US$ 5.4 million) from RMB 48.9 million in Q2 2024 [8] - General and administrative expenses dropped by 66.1% to RMB 31.4 million (US$ 4.4 million) from RMB 92.8 million in Q2 2024 [9] Revenue Breakdown - Revenue from in-hospital business increased by 4.4% to RMB 62.5 million (US$ 8.7 million) from RMB 59.9 million in Q2 2024 [7] - Revenue from central laboratory business decreased by 16.2% to RMB 40.9 million (US$ 5.7 million) from RMB 48.8 million in Q2 2024 [7] - Revenue from pharma research and development services surged by 68.1% to RMB 45.2 million (US$ 6.3 million) from RMB 26.9 million in Q2 2024 [7] Net Loss and Cash Position - The net loss for Q2 2025 was RMB 9.7 million (US$ 1.4 million), a significant reduction from RMB 108.0 million in Q2 2024 [9] - As of June 30, 2025, cash, cash equivalents, and restricted cash totaled RMB 455.0 million (US$ 63.5 million) [9]